adplus-dvertising
Connect with us

Business

When could Canada approve Moderna’s COVID-19 vaccine? Here’s what we know – Global News

Published

 on


EDITOR’S NOTE: A press release issued Monday morning said Health Canada was still awaiting data from Moderna and that authorization of its vaccine candidate was likely to take several more weeks. Officials later said that press release was from Friday and it was unclear why it had been re-issued on Monday morning.

It remains unclear when Canadians could see the highly anticipated Moderna vaccine approved for use in this country, even as the U.S. begins moving forward following authorization for the vaccine on Friday.

Health Canada faced questions on Monday about a press release it issued that morning saying Moderna still needed to submit more data to the health agency and that approval was likely still weeks away in Canada.

But officials said later in the morning, when pressed for more details, that the press release was actually from Friday and were unclear why it appears to have been re-issued to reporters again on Monday morning.

Story continues below advertisement

Read more:
U.S. gets 2nd coronavirus vaccine after FDA gives Moderna green light

The United States approved the emergency use of the Moderna vaccine on Friday as cases continue to soar within the country’s borders. Health Canada said it is “working closely” with international regulators, including the U.S. Food and Drug Administration, to exchange information on the vaccine candidates undergoing review.


Click to play video 'Coronavirus: U.S. gets 2nd COVID-19 vaccine after FDA gives Moderna green light'



2:25
Coronavirus: U.S. gets 2nd COVID-19 vaccine after FDA gives Moderna green light


Coronavirus: U.S. gets 2nd COVID-19 vaccine after FDA gives Moderna green light

Last Tuesday, the chief medical adviser at Health Canada said things “look positive” with respect to the Moderna vaccine, and that Canada was on track to make its decision about the vaccine very soon. She noted that the only outstanding information Canada needed was the data on manufacturing plants – documents that were supposed to be delivered by the end of last week.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

However, as of Monday morning, it appears Canada may still be waiting for some information.

Story continues below advertisement

“There is still information and data to be provided by Moderna for review,” read the Friday press release, which was sent to reporters again on Monday morning.

“Health Canada cannot provide a definite timeline for the completion of the review at this time, although it is expected to be completed in the coming weeks.”

When Health Canada obtained all the data from Pfizer on its vaccine candidate, it took just five days for the vaccine to be approved. But Canada was more familiar with Pfizer’s manufacturing facilities, so a review of Moderna’s facilities – which Canada has never reviewed before – may take a bit longer.

Once that approval comes down, Trudeau said doses will begin to arrive within 48 hours – and Canada has inked a deal that would see 168,000 Moderna vaccine doses arriving before the end of the month.


Click to play video 'Coronavirus: Canada secures 2nd agreement with Moderna for early vaccine doses'



1:32
Coronavirus: Canada secures 2nd agreement with Moderna for early vaccine doses


Coronavirus: Canada secures 2nd agreement with Moderna for early vaccine doses

Moderna doesn’t require the same level of ultra-cold storage as the Pfizer vaccine, making its approval all the more important for Canadians living in remote regions. Because of these logistical struggles, Canada’s three territories have been promised enough Moderna vaccine doses to inoculate 75 per cent of their residents.

Story continues below advertisement

As they await the vaccine’s approval and arrival, however, the virus continues to spread. And while Nunavut had remained untouched by the virus until November, the territory reported its first coronavirus deaths on Sunday.


Click to play video 'Coronavirus: Trudeau says majority of Canadians could be vaccinated by next September'



1:59
Coronavirus: Trudeau says majority of Canadians could be vaccinated by next September


Coronavirus: Trudeau says majority of Canadians could be vaccinated by next September – Nov 27, 2020

Once the Moderna vaccine is approved, Canada will be firmly placed on a track towards attaining its projected vaccination timeline. While Canada has signed purchase agreements with multiple vaccine manufacturers, the agreements with Moderna and Pfizer alone should see 60 million doses arrive in Canada by September.

That’s enough to vaccine 30 million Canadians, just eight million shy of the entire population.

Meanwhile, Health Canada says it’s working as fast as it can to ensure the Moderna vaccine doses – and any other vaccine candidates – are safe for use in Canada.

“Health Canada is working hard to give Canadians access to COVID-19 vaccines as quickly as possible and will not compromise its safety, efficacy and quality standards,” Health Canada wrote in its press release.

Story continues below advertisement

“Protecting the health and safety of Canadians is a top priority.”

© 2020 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending